• Brodalumab is a fully human anti–interleukin-17 receptor A monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis
• Brodalumab demonstrated rapid and robust levels of skin clearance in a 12-week, double-blind, phase 2 study in patients with psoriasis.

**OBJECTIVE**

• To evaluate the long-term efficacy and safety of brodalumab in an open-label extension (OLE) of the phase 2 study

**METHODS**

• In the parent study, patients were randomized to brodalumab (70, 140, 210, or 280 mg) or placebo for 12 weeks.
• All patients in the OLE initially received brodalumab 210 mg every 2 weeks (Q2W).
• Dose reduction to brodalumab 140 mg Q2W was later allowed in patients weighing ≥100 kg with a subsequent dose increase to brodalumab 210 mg Q2W in patients with an inadequate response to brodalumab 140 mg Q2W.
• Efficacy was assessed by psoriasis area and severity index (PASI) 75% improvement response (PASI 75) and PASI 100 (observed data analysis).
• Other assessments included the percentage of patients with a dermatology life quality index (DLQI), dermatology quality of life scores, and was well tolerated through ~5 years of long-term treatment.

**RESULTS**

Patient population: A total of 181 patients (87 men and 94 women; mean [standard deviation] age, 42.7 [12.2] years; 90% white) entered the OLE; 107 patients had an efficacy evaluation at week 264.

Efficacy: Efficacy with brodalumab was maintained from week 12 up to week 264, with PASI 75 responses consistently ≥80% and PASI 100 responses consistently ≥94% (Figure 1).

Safety: No new safety signals emerged in the OLE period.

**CONCLUSIONS**

• Brodalumab demonstrated high levels of skin clearance efficacy, improved dermatology quality of life scores, and was well tolerated through ~5 years of long-term treatment.
• Complete skin clearance (PASI 100) with brodalumab was associated with improved quality of life relative to high levels of efficacy without complete skin clearance (PASI 75 to <100).

**Acknowledgments:** The brodalumab clinical study program was sponsored by Amgen/AstraZeneca and this analysis was performed by Ortho Dermatologics, Medical writing support was provided by MA Medical Communications, and the data were reviewed by Ortho Dermatologics. Ortho Dermatologics is a division of Bausch Health US LLC.

**Preprint presentation information:** Data in this poster were previously presented at Maui Derm for Dermatologists, January 26–30, 2019, Maui, HI and 43rd Annual Hawaii Dermatology Seminar, February 17–20, 2019, The Big Island, HI.